Biopharmaceutical Development: Innovations Impacting Development
BioPharm International® spoke with Oury Chetboun, CEO of Seekyo Therapeutics, to get his perspective on what impact new modalities and technology innovations are having on biopharmaceutical development.
The biopharma industry is seeing growth in innovation with new treatments for cancer and autoimmune diseases and the development of specialized medicines. New technologies, such as artificial intelligence and machine learning, are also having an impact on drug development and manufacturing.
New drugs come with the cost to develop and produce before they can reach patients. According to Oury Chetboun, CEO of Seekyo Therapeutics, one trend that is advancing the biopharma industry is continuous manufacturing, which can reduce time to market. “You may have a fantastic drug [in the lab] which costs [a] massive [amount] to be scaled up, but if you can't get that into a large-scale production or at a reasonable cost, then you can't do anything,” Chetboun cautions.
Click the video above to watch the full interview.
About the speaker
Oury Chetboun is CEO of Seekyo Therapeutics. He has a background in immunology and has been working in business development for 20 years. Seekyo develops solid cancer treatments that target functional proteins.
Psilera, Hesperos Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
